Effects of Coffee on Hepatic Steatosis Induced by a High Fructose Diet
- Conditions
- Hepatic Steatosis
- Interventions
- Dietary Supplement: CtlDietary Supplement: High fructose diet; no coffeeDietary Supplement: fully torrefied, caffeine-free coffeeDietary Supplement: partially torrefied, caffeine-free coffeeDietary Supplement: Partially torrefied, caffeinated coffee
- Registration Number
- NCT00827450
- Lead Sponsor
- University of Lausanne
- Brief Summary
This study will assess
* whether coffee consumption protects against fructose-induced hepatic steatosis in healthy humans
* whether the protective effect of coffee is dependent on it's antioxidant composition
- Detailed Description
Epidemiological studies suggest that coffee consumption improves glucose homeostasis in insulin resistant subjects. An increase in intrahepatic lipids (hepatic steatosis) is highly prevalent in patients with the metabolic syndrome and may be used as a marker of altered hepatic lipid metabolism. Such an increased hepatic lipids content can be experimentally produced in healthy humans by a 6-day high fructose diet.
The purpose of this study is to evaluate whether coffee prevents hepatic lipid deposition in healthy male subjects fed a fructose-rich hypercaloric diet. Both caffeine and antioxidants (yet unspecified) may be involved.. To sort out the role of caffeine and antioxidants, we will test 3 different soluble coffee, ie fully torrefied decaffeinated coffee , partially torrefied decaffeinated coffee, and partially torrefied caffeinated coffee.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Male
- Target Recruitment
- 13
- BMI between 19 and 15 kg/m2
- less than 30 min physical activity /day
- habitual coffee consumption less than three cupy /day
- consumption of caffeine-containing sodas less than 2 servings/day
- non-smoker
- consumption of alcohol more than 40g/day
- presence of metallic foreign bodies
- history of eye surgery
- family history of diabetes mellitus
- history of food intolerance
- vegetarians
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- FACTORIAL
- Arm && Interventions
Group Intervention Description Ctl Ctl control isocaloric diet; no coffee HF High fructose diet; no coffee Hypercaloric. high fructose diet; no coffee C1 fully torrefied, caffeine-free coffee Hypercaloric, high fructose diet; caffeine-free, torrefied coffee C2 partially torrefied, caffeine-free coffee Hypercaloric, high fructose diet; caffeine-free, partially torrefied coffee C3 Partially torrefied, caffeinated coffee Hypercaloric, high fructose diet; caffeinated, partially torrefied coffee
- Primary Outcome Measures
Name Time Method intra-hepatocellular lipid (IHCL) concentration will be measured after 6 days on a hypercaloric, high fructose (4g/kg body weight/day) diet +/- treatement
- Secondary Outcome Measures
Name Time Method fasting plasma triglycerides will be measured after 6 days on a hypercaloric, high fructose (4g/kg body weight/day) diet +/- treatement fasting net lipid oxidation will be measured after 6 days on a hypercaloric, high fructose (4g/kg body weight/day) diet +/- treatement fasting net carbohydrate oxidation will be measured after 6 days on a hypercaloric, high fructose (4g/kg body weight/day) diet +/- treatement whole body ketone bodies turnover and oxidation (13C 3-hydroxybutyrate) will be measured after 6 days on a hypercaloric, high fructose (4g/kg body weight/day) diet +/- treatement whole body glucose turnover (6,6 2H2 glucose) will be measured after 6 days on a hypercaloric, high fructose (4g/kg body weight/day) diet +/- treatement whole body glycerol turnover (2H5 glycerol) will be measured after 6 days on a hypercaloric, high fructose (4g/kg body weight/day) diet +/- treatement
Trial Locations
- Locations (1)
Centre d'investigations cliniques "cardiomet"/ CHUV
🇨ðŸ‡Lausanne, Switzerland